Tag: cellular immunotherapy market share

Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Predicted Market Size Of The Cellular Immunotherapy Industry By 2029?

The market size of cellular immunotherapy has seen rapid expansion in the recent past. It is projected to escalate from a value of $5.72 billion in 2024 to $6.56 billion in 2025, with a Compound Annual Growth Rate (CAGR) standing at 14.7%. Factors such as advancement in cancer therapies, cases of successful clinical outcomes, regulatory accreditations, and an increasing occurrence of targeted diseases have contributed significantly to the growth experienced during the historical period.

The market size for cellular immunotherapy is projected to expand swiftly in the forthcoming years, reaching an estimated value of “$11.03 billion by 2029, with a compound annual growth rate (CAGR) of 13.9%. The predicted growth during this forecasted period can be credited to several factors, such as the increased focus on solid tumours, advancements in manufacturing processes, improved healthcare facilities, and increased funds allocated for research. Key trends for the forecast period include investment in research and development, data from clinical trials, and the rise of combination therapies.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3435&type=smp

What Core Drivers Are Expected To Influence The Cellular Immunotherapy Market?

The anticipated expansion of the cellular immunotherapy market is predicted due to the increased research and successful clinical trials in this field. There is a concentrated effort amongst companies to develop novel cellular immunotherapies for a variety of diseases. As an example, the Cancer Research Institute, a non-profit organization based in the United States dedicated to the advancement of immunotherapy for the prevention, treatment, and eradication of all forms of cancer, released a report in June 2022 stating that as of April that same year, the global immuno-oncology pipeline included 2,756 active cell therapy drugs. This reflects an increase of 36% from the landscape analysis conducted in 2021, which revealed the existence of 2,031 drugs, but also demonstrates a decrease in growth from the previous year’s 43%. The remarkable growth in cellular immunotherapy development both at the clinical and preclinical stages in 2020 compared to 2019 is likely to extend the reach of cellular immunotherapy further, consequently driving the generation of higher revenues for the advancement of the market.

What Is The Segment Breakdown Of The Cellular Immunotherapy Market?

The cellular immunotherapy market covered in this report is segmented –

1) By Therapy: Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy

2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications

3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications

Subsegments:

1) By Tumour-Infiltrating Lymphocyte (TIL) Therapy: Autologous TIL Therapy, Allogeneic TIL Therapy, Other TIL Therapy

2) By Engineered T Cell Receptor (TCR) Therapy: Alpha-Beta TCR Therapy, Gamma-Delta TCR Therapy, Other Engineered TCR Therapy

3) By Chimeric Antigen Receptor (CAR) T Cell Therapy: Autologous CAR T Cell Therapy, Allogeneic CAR T Cell Therapy, CAR T Cell Therapy For Solid Tumors, CAR T Cell Therapy For Hematologic Malignancies, Other CAR T Cell Therapy

4) By Natural Killer (NK) Cell Therapy: Autologous NK Cell Therapy, Allogeneic NK Cell Therapy, NK Cell Therapy With Engineered Modifications, Other NK Cell Therapy

How Are Global Trends Impacting The Development Of The Cellular Immunotherapy Market?

Firms in the cellular immunotherapy market are turning their attention towards creating off-the-shelf allogeneic therapies as a novel and more effective approach to combat cancer. These therapies, unlike autologous treatments, are derived from donor cells rather than the patient’s own cells. Benefits of these non-personalized treatments include cost efficiency, mass production, rapid development, and quality assurance. For example, in May 2022, the Switzerland-based pharmaceutical firm Novartis AG, known for its commitment to discovering, developing, manufacturing, and marketing drugs, received rapid approval from the US Food and Drug Administration (FDA) to use Kymriah (tisagenlecleucel) for treating adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more courses of systemic therapy. Additionally, Acepodia, an American cell immuno-technology company specialized in next-generation treatment, is set to initiate a phase 1 clinical trial in August 2020 for ACE1702, an allogeneic, off-the-shelf NK cell therapy intended for treating solid tumors.

Which Firms Are Driving Innovation Within The Cellular Immunotherapy Market?

Major companies operating in the cellular immunotherapy market include Novartis International AG, Gilead Sciences Inc., Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp, AstraZeneca plc, Bristol Myers Squibb Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Adicet Bio Inc., ResTORbio Inc., Celyad SA, Merck KGaA, GlaxoSmithKline plc., Johnson & Johnson, Adaptimmune Therapeutics plc, AVROBIO Inc., Cellular Biomedicine Group Inc., Kite Pharma Inc., Juno Therapeutics Inc., Celgene Corporation, Bluebird Bio Inc., Tmunity Therapeutics Inc., Atara Biotherapeutics Inc., Fate Therapeutics Inc., Precision Biosciences Inc., Allogene Therapeutics Inc., CRISPR Therapeutics AG, Sangamo Therapeutics Inc., Intellia Therapeutics Inc., Editas Medicine Inc., Caribou Biosciences Inc., Mammoth Biosciences Inc., Synthego Corporation

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

Which Region Is Likely To Register The Fastest Growth In The Cellular Immunotherapy Market?

North America was the largest region in the cellular immunotherapy market in 2024. The regions covered in the cellular immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=3435&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_

_x000D_

#What Is the Outlook for the Wellness Supplements Market Heading Into 2029?#_x000D_

The rapidly expanding market size of cellular immunotherapy has seen considerable growth in recent years. The forecast projects an increase from $5.72 billion in 2024 to $6.56 billion in 2025, reflecting a compound annual growth rate (CAGR) of 14.7%. This growth during the previous years is largely due to progress in cancer treatments, effective clinical outcomes, regulatory authorizations, and an increasing prevalence of targeted diseases._x000D_

_x000D_

The market for cellular immunotherapy is projected to experience substantial expansion in the forthcoming years. It is anticipated to reach “$11.03 billion by 2029, growing at a compound annual growth rate (CAGR) of 13.9%. The predicted growth during the forecast period is credited to advancements in solid tumor treatments, enhanced manufacturing, healthcare infrastructure, and research funding. Prevailing trends for the projected period feature investments in research and development, data from clinical trials, and combined therapy methods._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=3435&type=smp_x000D_

_x000D_

#Which Factors Are Pushing The Wellness Supplements Market Forward?#_x000D_

The wellness supplements market is anticipated to see significant growth due to an increasing emphasis on maintaining a healthy lifestyle. By maintaining a lifestyle that includes regular exercise, a balanced diet, sufficient rest, and the consumption of wellness supplements, individuals can boost their energy levels and decrease their risk of illness. Thus people are encouraged to incorporate wellness supplements into their everyday regime. For example, the International Food Information Council – a nonprofit supported by the food, beverage, and agricultural industries – reported in May 2022 that there has been an increase in diet or eating pattern followers; from 39% in 2021 to 52% in 2022 amongst Americans. Hence, the rise in interest towards healthy living is enhancing the growth of the wellness supplements market._x000D_

_x000D_

_x000D_

The cellular immunotherapy market covered in this report is segmented – _x000D_

_x000D_

1) By Therapy: Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy _x000D_

2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications_x000D_

3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications _x000D_

_x000D_

Subsegments:_x000D_

1) By Tumour-Infiltrating Lymphocyte (TIL) Therapy: Autologous TIL Therapy, Allogeneic TIL Therapy, Other TIL Therapy_x000D_

2) By Engineered T Cell Receptor (TCR) Therapy: Alpha-Beta TCR Therapy, Gamma-Delta TCR Therapy, Other Engineered TCR Therapy_x000D_

3) By Chimeric Antigen Receptor (CAR) T Cell Therapy: Autologous CAR T Cell Therapy, Allogeneic CAR T Cell Therapy, CAR T Cell Therapy For Solid Tumors, CAR T Cell Therapy For Hematologic Malignancies, Other CAR T Cell Therapy_x000D_

4) By Natural Killer (NK) Cell Therapy: Autologous NK Cell Therapy, Allogeneic NK Cell Therapy, NK Cell Therapy With Engineered Modifications, Other NK Cell Therapy_x000D_

_x000D_

#What Trends Are Currently Influencing Growth In The Wellness Supplements Market?#_x000D_

In the cellular immunotherapy market, corporations are shifting their attention towards the creation of enhanced cancer therapies using novel off-the-shelf allogeneic treatments. Unlike autologous therapy which uses the patient’s cells, allogeneic therapies involve cells from a donor. This generic approach offers several advantages, including cost-effectiveness, large-scale and rapid production, and quality control. As an example, in May 2022, the US Food and Drug Administration (FDA) approved an expedited approval for Kymriah (tisagenlecleucel) after two or more lines of systemic therapy were tried, according to Novartis AG. The Swiss-based pharmaceutical company specializes in the discovery, development, manufacturing, and commercialization of drugs, and its new therapy will be used to treat adult patients suffering from relapsed or refractory (r/r) follicular lymphoma (FL). Additionally, Acepodia, a US-based novel cell immuno-technology company, will launch a phase 1 clinical trial in August 2020 to assess the potential of ACE1702, an off-the-shelf NK cell therapy created from allogeneic resources, to treat solid tumors._x000D_

_x000D_

#Which Organizations Are Driving Progress In The Wellness Supplements Industry?#_x000D_

Major companies operating in the cellular immunotherapy market include Novartis International AG, Gilead Sciences Inc., Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp, AstraZeneca plc, Bristol Myers Squibb Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Adicet Bio Inc., ResTORbio Inc., Celyad SA, Merck KGaA, GlaxoSmithKline plc., Johnson & Johnson, Adaptimmune Therapeutics plc, AVROBIO Inc., Cellular Biomedicine Group Inc., Kite Pharma Inc., Juno Therapeutics Inc., Celgene Corporation, Bluebird Bio Inc., Tmunity Therapeutics Inc., Atara Biotherapeutics Inc., Fate Therapeutics Inc., Precision Biosciences Inc., Allogene Therapeutics Inc., CRISPR Therapeutics AG, Sangamo Therapeutics Inc., Intellia Therapeutics Inc., Editas Medicine Inc., Caribou Biosciences Inc., Mammoth Biosciences Inc., Synthego Corporation_x000D_

_x000D_

_x000D_

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report_x000D_

_x000D_

#Which Region Is Expected To Experience The Highest Growth In The Wellness Supplements Industry?#_x000D_

North America was the largest region in the cellular immunotherapy market in 2024. The regions covered in the cellular immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa_x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=3435&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Key Projections for the CAGR of the Cellular Immunotherapy Market Size From 2025 to 2034?

The market size for cellular immunotherapy has seen a quick rise in the past few years. The forecasted growth stages it to expand from $5.72 billion in 2024 to $6.56 billion in 2025, projecting a compound annual growth rate (CAGR) of 14.7%. This significant growth during the historical period is linked to developments in cancer treatment, triumphant clinical anecdotes, regulatory endorsements, and an increasing occurrence of targeted diseases.

The size of the cellular immunotherapy market is projected to experience swift expansion in the upcoming years, surging to a value of $11.03 billion by 2029, portraying a compound annual growth rate (CAGR) of 13.9%. Factors contributing to this growth during the projected period include advancements in treating solid tumors, enhancements in manufacturing and healthcare infrastructure, and increases in research funding. The forecast period is also anticipated to witness significant developments, including investments in research and development, clinical trial data, and the advent of combination therapies.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3435&type=smp

Which Factors and External Forces Are Driving Demand in the Cellular Immunotherapy Market?

The cellular immunotherapy market’s growth is anticipated to be fuelled by escalating research efforts and successful clinical trials in this field during the forecast period. Various companies are concentrating on the production of innovative cellular immunotherapies to combat various conditions. As an example, the Cancer Research Institute, an American non-profit organisation committed to creating immunotherapy for the prevention, treatment and removal of all types of cancer, issued a report in June 2022 stating that as of April 2022, there were 2,756 operational cell therapy drugs globally in the immuno-oncology pipeline. This is a growth of 36% from 2021, which had 2,031 such therapies – a slight decline from the 43% growth reported in the preceding year. The substantial increase in the number of cellular immunotherapies in clinical trials and preclinical stages in 2020, compared to those in 2019, is predicted to widen the spectrum of cellular immunotherapy, thus contributing to more substantial revenue generation and expansion of the cellular immunotherapy market.

Which Segments in the Cellular Immunotherapy Offer the Most Growth?

The cellular immunotherapy market covered in this report is segmented –

1) By Therapy: Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy

2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications

3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications

Subsegments:

1) By Tumour-Infiltrating Lymphocyte (TIL) Therapy: Autologous TIL Therapy, Allogeneic TIL Therapy, Other TIL Therapy

2) By Engineered T Cell Receptor (TCR) Therapy: Alpha-Beta TCR Therapy, Gamma-Delta TCR Therapy, Other Engineered TCR Therapy

3) By Chimeric Antigen Receptor (CAR) T Cell Therapy: Autologous CAR T Cell Therapy, Allogeneic CAR T Cell Therapy, CAR T Cell Therapy For Solid Tumors, CAR T Cell Therapy For Hematologic Malignancies, Other CAR T Cell Therapy

4) By Natural Killer (NK) Cell Therapy: Autologous NK Cell Therapy, Allogeneic NK Cell Therapy, NK Cell Therapy With Engineered Modifications, Other NK Cell Therapy

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=3435&type=smp

What Are the Fastest-Growing Geographies in the #Which Factors and External Forces Are Driving Demand in the Cellular Immunotherapy Market?# Market?

North America was the largest region in the cellular immunotherapy market in 2024. The regions covered in the cellular immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Which Cutting-Edge Market Trends Are Expected to Drive theCellular Immunotherapy Market’s Growth?

In the cellular immunotherapy market, the focus is shifting towards the creation of off-the-shelf allogeneic therapies for enhanced cancer treatment. These therapies differ from traditional autologous therapy in that they are derived from donor cells rather than the cells of the patient. The uniform nature of these therapies offers benefits such as cost efficiency, mass production, swift production, and quality assurance. For example, in May 2022, the US FDA approved Kymriah (tisagenlecleucel) for the treatment of adult patients with relapsing or refractory (r/r) follicular lymphoma (FL) after two or more courses of systemic therapy. This announcement was made by Novartis AG, a Swiss pharmaceutical firm with expertise in drug discovery, development, production, and commercialization. Furthermore, Acepodia, a US biotech firm specializing in next-generation cell immunotherapy, is set to commence a phase 1 clinical trial in August 2020 to assess the efficacy of ACE1702, an allogeneic, off-the-shelf NK cell therapy, in treating solid tumors.

View the full report here:

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

What Are the Key Elements That Define the Cellular Immunotherapy Market?

Cellular immunotherapy refers to a sort of immunotherapy in which a patient receives T cells, an immune cell, to aid the body in fighting diseases like cancer. It is a cutting-edge kind of treatment that uses the body’s immune system to combat cancer.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3435

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has the Cellular Immunotherapy Market Growth Performance Trended Historically, And What Lies Ahead?

In recent times, the market size of cellular immunotherapy has seen swift expansion. It is projected to rise from $5.72 billion in 2024 to $6.61 billion in 2025, boasting a compound annual growth rate (CAGR) of 15.7%. Factors such as advancements in cancer treatment, clinical achievements, regulatory sanctions, and the escalating prevalence of targeted diseases have all contributed to the growth in the historic period.

What Is the Forecast for the Cellular Immunotherapy Market Size Through 2029?

It is projected that the cellular immunotherapy market will experience rapid expansion in the upcoming years, reaching a value of $11.27 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 14.2%. This growth during the forecast period can be ascribed to factors such as the growth of solid tumors, advancements in manufacturing techniques, improvement of healthcare infrastructure, and increased funding for research. Key trends forecasted for this period include a rise in research and development investments, the availability of clinical trial data, and the use of combination therapies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3435&type=smp

What are the Key Market Players in Cellular Immunotherapy Market and How They’re Evolving?

Major companies operating in the cellular immunotherapy market include Novartis International AG, Gilead Sciences Inc., Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp, AstraZeneca plc, Bristol Myers Squibb Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Adicet Bio Inc., ResTORbio Inc., Celyad SA, Merck KGaA, GlaxoSmithKline plc., Johnson & Johnson, Adaptimmune Therapeutics plc, AVROBIO Inc., Cellular Biomedicine Group Inc., Kite Pharma Inc., Juno Therapeutics Inc., Celgene Corporation, Bluebird Bio Inc., Tmunity Therapeutics Inc., Atara Biotherapeutics Inc., Fate Therapeutics Inc., Precision Biosciences Inc., Allogene Therapeutics Inc., CRISPR Therapeutics AG, Sangamo Therapeutics Inc., Intellia Therapeutics Inc., Editas Medicine Inc., Caribou Biosciences Inc., Mammoth Biosciences Inc., Synthego Corporation

What Are the Primary Growth Drivers in the Cellular Immunotherapy Market?

The surge in research activities and successful outcomes of clinical experiments in cellular immunotherapy are projected to fuel the expansion of the cellular immunotherapy market in the foreseeable future. With a targeted focus on creating new cellular immunotherapies for a range of diseases, companies are stepping up their efforts. The Cancer Research Institute, for example, a US-based nonprofit organization exclusively devoted to advancing immunotherapy for the prevention, treatment, and ultimate extermination of all cancers, reported in June 2022 that there were 2,756 active cell therapy drugs in the global immuno-oncology pipeline as of April 2022. This signifies a 36% growth from the 2021 landscape analysis, which listed 2,031 such agents, but also marks a slight drop from the 43% growth in the prior year. The quick-paced progression in the field of cellular immunotherapy at both clinical and preclinical stages in 2020, as compared to 2019, is anticipated to broaden the scope of cellular immunotherapy, leading to increased revenue generation for the cellular immunotherapy market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=3435&type=smp

What Are the Leading Segments in the Global Cellular Immunotherapy Industry?

The cellular immunotherapy market covered in this report is segmented –

1) By Therapy: Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy

2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications

3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications

Subsegments:

1) By Tumour-Infiltrating Lymphocyte (TIL) Therapy: Autologous TIL Therapy, Allogeneic TIL Therapy, Other TIL Therapy

2) By Engineered T Cell Receptor (TCR) Therapy: Alpha-Beta TCR Therapy, Gamma-Delta TCR Therapy, Other Engineered TCR Therapy

3) By Chimeric Antigen Receptor (CAR) T Cell Therapy: Autologous CAR T Cell Therapy, Allogeneic CAR T Cell Therapy, CAR T Cell Therapy For Solid Tumors, CAR T Cell Therapy For Hematologic Malignancies, Other CAR T Cell Therapy

4) By Natural Killer (NK) Cell Therapy: Autologous NK Cell Therapy, Allogeneic NK Cell Therapy, NK Cell Therapy With Engineered Modifications, Other NK Cell Therapy

What Are the Key Market Trends in the Cellular Immunotherapy Industry?

Firms operating within the cellular immunotherapy market are increasingly focusing on enhancing cancer treatment through the creation of off-the-shelf allogeneic therapies. These therapies are developed from donor cells, unlike autologous treatment that uses the patient’s own cells. The advantages of this approach include cost-efficiency, potential for large-scale production, speedy production, and enhanced quality management. For example, in May 2022, Novartis AG, a Swiss pharmaceutical firm specializing in the research, development, production, and distribution of medications, declared that the US Food and Drug Administration (FDA) has swiftly approved the use of Kymriah (tisagenlecleucel), for adults with relapsed or refractory follicular lymphoma (FL), following at least two lines of systemic therapy. Furthermore, Acepodia, a U.S.-based firm operating in the cell immunotechnology sphere, is set to commence a phase 1 clinical trial in August 2020, to study ACE1702, an allogeneic, off-the-shelf NK cell therapy, for the treatment of solid tumors.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

What Is the Regional Outlook for the Cellular Immunotherapy Market?

North America was the largest region in the cellular immunotherapy market in 2023. The regions covered in the cellular immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3435

This Report Delivers Insight On:

1. How big is the cellular immunotherapy market, and how is it changing globally?

2. Who are the major companies in the cellular immunotherapy market, and how are they performing?

3. What are the key opportunities and risks in the cellular immunotherapy market right now?

4. Which products or customer segments are growing the most in the cellular immunotherapy market?

5. What factors are helping or slowing down the growth of the cellular immunotherapy market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#How Has the Cellular Immunotherapy Market Growth Performance Trended Historically, And What Lies Ahead?

In recent times, the market size of cellular immunotherapy has seen swift expansion. It is projected to rise from $5.72 billion in 2024 to $6.61 billion in 2025, boasting a compound annual growth rate (CAGR) of 15.7%. Factors such as advancements in cancer treatment, clinical achievements, regulatory sanctions, and the escalating prevalence of targeted diseases have all contributed to the growth in the historic period.

What Is the Forecast for the Cellular Immunotherapy Market Size Through 2029?

It is projected that the cellular immunotherapy market will experience rapid expansion in the upcoming years, reaching a value of $11.27 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 14.2%. This growth during the forecast period can be ascribed to factors such as the growth of solid tumors, advancements in manufacturing techniques, improvement of healthcare infrastructure, and increased funding for research. Key trends forecasted for this period include a rise in research and development investments, the availability of clinical trial data, and the use of combination therapies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3435&type=smp

What are the Key Market Players in Cellular Immunotherapy Market and How They’re Evolving?

Major companies operating in the cellular immunotherapy market include Novartis International AG, Gilead Sciences Inc., Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp, AstraZeneca plc, Bristol Myers Squibb Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Adicet Bio Inc., ResTORbio Inc., Celyad SA, Merck KGaA, GlaxoSmithKline plc., Johnson & Johnson, Adaptimmune Therapeutics plc, AVROBIO Inc., Cellular Biomedicine Group Inc., Kite Pharma Inc., Juno Therapeutics Inc., Celgene Corporation, Bluebird Bio Inc., Tmunity Therapeutics Inc., Atara Biotherapeutics Inc., Fate Therapeutics Inc., Precision Biosciences Inc., Allogene Therapeutics Inc., CRISPR Therapeutics AG, Sangamo Therapeutics Inc., Intellia Therapeutics Inc., Editas Medicine Inc., Caribou Biosciences Inc., Mammoth Biosciences Inc., Synthego Corporation

What Are the Primary Growth Drivers in the Cellular Immunotherapy Market?

The surge in research activities and successful outcomes of clinical experiments in cellular immunotherapy are projected to fuel the expansion of the cellular immunotherapy market in the foreseeable future. With a targeted focus on creating new cellular immunotherapies for a range of diseases, companies are stepping up their efforts. The Cancer Research Institute, for example, a US-based nonprofit organization exclusively devoted to advancing immunotherapy for the prevention, treatment, and ultimate extermination of all cancers, reported in June 2022 that there were 2,756 active cell therapy drugs in the global immuno-oncology pipeline as of April 2022. This signifies a 36% growth from the 2021 landscape analysis, which listed 2,031 such agents, but also marks a slight drop from the 43% growth in the prior year. The quick-paced progression in the field of cellular immunotherapy at both clinical and preclinical stages in 2020, as compared to 2019, is anticipated to broaden the scope of cellular immunotherapy, leading to increased revenue generation for the cellular immunotherapy market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=3435&type=smp

What Are the Leading Segments in the Global Cellular Immunotherapy Industry?

The cellular immunotherapy market covered in this report is segmented –

1) By Therapy: Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy

2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications

3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications

Subsegments:

1) By Tumour-Infiltrating Lymphocyte (TIL) Therapy: Autologous TIL Therapy, Allogeneic TIL Therapy, Other TIL Therapy

2) By Engineered T Cell Receptor (TCR) Therapy: Alpha-Beta TCR Therapy, Gamma-Delta TCR Therapy, Other Engineered TCR Therapy

3) By Chimeric Antigen Receptor (CAR) T Cell Therapy: Autologous CAR T Cell Therapy, Allogeneic CAR T Cell Therapy, CAR T Cell Therapy For Solid Tumors, CAR T Cell Therapy For Hematologic Malignancies, Other CAR T Cell Therapy

4) By Natural Killer (NK) Cell Therapy: Autologous NK Cell Therapy, Allogeneic NK Cell Therapy, NK Cell Therapy With Engineered Modifications, Other NK Cell Therapy

What Are the Key Market Trends in the Cellular Immunotherapy Industry?

Firms operating within the cellular immunotherapy market are increasingly focusing on enhancing cancer treatment through the creation of off-the-shelf allogeneic therapies. These therapies are developed from donor cells, unlike autologous treatment that uses the patient’s own cells. The advantages of this approach include cost-efficiency, potential for large-scale production, speedy production, and enhanced quality management. For example, in May 2022, Novartis AG, a Swiss pharmaceutical firm specializing in the research, development, production, and distribution of medications, declared that the US Food and Drug Administration (FDA) has swiftly approved the use of Kymriah (tisagenlecleucel), for adults with relapsed or refractory follicular lymphoma (FL), following at least two lines of systemic therapy. Furthermore, Acepodia, a U.S.-based firm operating in the cell immunotechnology sphere, is set to commence a phase 1 clinical trial in August 2020, to study ACE1702, an allogeneic, off-the-shelf NK cell therapy, for the treatment of solid tumors.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

What Is the Regional Outlook for the Cellular Immunotherapy Market?

North America was the largest region in the cellular immunotherapy market in 2023. The regions covered in the cellular immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3435

This Report Delivers Insight On:

1. How big is the cellular immunotherapy market, and how is it changing globally?

2. Who are the major companies in the cellular immunotherapy market, and how are they performing?

3. What are the key opportunities and risks in the cellular immunotherapy market right now?

4. Which products or customer segments are growing the most in the cellular immunotherapy market?

5. What factors are helping or slowing down the growth of the cellular immunotherapy market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the cellular immunotherapy industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Fast Is The Cellular Immunotherapy Market Expected to Grow Between 2025 And 2029?

The size of the cellular immunotherapy market has seen a quick expansion in the past few years. The market, which stands at $5.72 billion in 2024, is expected to increase to $6.61 billion in 2025, reflecting a compound annual growth rate (CAGR) of 15.7%. The expansion during the historic period can be associated with advancements in cancer treatment, clinical triumphs, regulatory endorsements, and an escalating incidence of targeted diseases.

The market size of cellular immunotherapy is predicted to witness exponential growth over the next few years. It’s estimated that by 2029, the market will be valued at $11.27 billion with a CAGR of 14.2%. The anticipated growth during this forecasted period can be linked to the expansion to solid tumors, enhancements in manufacturing, healthcare infrastructure, and funding for research. Key trends during the forecast period include investments in research and development, data from clinical trials, and combination therapies.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3435&type=smp

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the Cellular Immunotherapy Market?

The expected expansion of the cellular immunotherapy market is largely down to advanced research and the success of clinical trials in cellular immunotherapy. Companies are shifting their focus towards crafting new cellular immunotherapies to address various diseases. In an example reported by the Cancer Research Institute, a solo-operating nonprofit based in the US working towards the creation of immunotherapy for prohibiting, treating, and ultimately wiping out every form of cancer globally, there were 2,756 active cell therapy drugs as of April 2022 in the worldwide immuno-oncology pipeline. This is a 36% increase from the 2021 landscape analysis record of 2,031, albeit with a slight drop from the previous year’s growth rate of 43%. An accelerated pace of development was observed in cellular immunotherapy in both clinical and preclinical stages in 2020, compared to 2019, which is expected to widen the cellular immunotherapy landscape. This, in turn, is projected to boost revenues, contributing to the growth of the cellular immunotherapy market.

Which Segments in the Cellular Immunotherapy Offer the Most Growth?

The cellular immunotherapy market covered in this report is segmented –

1) By Therapy: Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy

2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications

3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications

Subsegments:

1) By Tumour-Infiltrating Lymphocyte (TIL) Therapy: Autologous TIL Therapy, Allogeneic TIL Therapy, Other TIL Therapy

2) By Engineered T Cell Receptor (TCR) Therapy: Alpha-Beta TCR Therapy, Gamma-Delta TCR Therapy, Other Engineered TCR Therapy

3) By Chimeric Antigen Receptor (CAR) T Cell Therapy: Autologous CAR T Cell Therapy, Allogeneic CAR T Cell Therapy, CAR T Cell Therapy For Solid Tumors, CAR T Cell Therapy For Hematologic Malignancies, Other CAR T Cell Therapy

4) By Natural Killer (NK) Cell Therapy: Autologous NK Cell Therapy, Allogeneic NK Cell Therapy, NK Cell Therapy With Engineered Modifications, Other NK Cell Therapy

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=3435&type=smp

What Are the Fastest-Growing Geographies in the Cellular Immunotherapy Market?

North America was the largest region in the cellular immunotherapy market in 2023. The regions covered in the cellular immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Which Cutting-Edge Market Trends Are Expected to Drive the Cellular Immunotherapy Market’s Growth?

Firms operating within the cellular immunotherapy sector are prioritizing the creation of off-the-shelf allogeneic treatments as a fresh and superior solution for cancer. These therapies, unlike autologous therapy, are generated using donor cells rather than the patient’s own cells. These non-customized treatments offer several benefits like cost-effectiveness, mass scale, rapid production, and quality management. In fact, Novartis AG, a pharmaceutical corporation situated in Switzerland that focuses on the research, development, manufacture, and marketing of medications, stated in May 2022 that the US Food and Drug Administration (FDA) has hastily approved Kymriah (tisagenlecleucel) for the treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after undergoing at least two systemic therapy lines. Furthermore, Acepodia, an American next-generation cell immuno-technology firm, plans to commence a phase 1 clinical trial in August 2020 to analyze ACE1702, an allogeneic, off-the-shelf NK cell therapy, in treating solid tumors.

View the full report here:

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

What Are the Key Elements That Define the Cellular Immunotherapy Market?

Cellular immunotherapy refers to a sort of immunotherapy in which a patient receives T cells, an immune cell, to aid the body in fighting diseases like cancer. It is a cutting-edge kind of treatment that uses the body’s immune system to combat cancer.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3435

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the cellular immunotherapy market size evolved in recent years?

The scale of the cellular immunotherapy market has been expanding swiftly in the past years. It is projected to escalate from $5.72 billion in 2024 to $6.61 billion in 2025, representing a compound annual growth rate (CAGR) of 15.7%. The growth witnessed in the earlier phase is attributed to progress in cancer treatment techniques, clinical triumphs, regulatory green lights and the increasing cases of targeted diseases.

What are the predictions for the cellular immunotherapy market size in the coming years?

Expectations are high for a swift expansion in the cellular immunotherapy market in the coming years. Predictions suggest an increase to $11.27 billion by 2029, translating to a compound annual growth rate (CAGR) of 14.2%. The anticipated growth during the forecast period can be associated with developments in solid tumors, enhanced manufacturing processes, improvements in healthcare infrastructure, and an increase in research funding. The forecast period is likely to witness substantial trends such as investment in research and development, data from clinical trials, and the emergence of combination therapies.

Get your cellular immunotherapy market report here!

https://www.thebusinessresearchcompany.com/sample.aspx?id=3435&type=smp

What key factors are fueling the growth of the cellular immunotherapy market?

The cellular immunotherapy market is anticipated to grow due to the rising scope of research and promising results from clinical trials in this area. Many companies are turning their attention to create new forms of cellular immunotherapies to combat various diseases. For instance, as per a report by the Cancer Research Institute in June 2022, a US-based organization committed to crafting immunotherapy for the prevention, treatment, and eventual elimination of all forms of cancer, there were 2,756 active cell therapy drugs in the global immuno-oncology pipeline as of April 2022. This marked a 36% rise from the overall tally of 2021 which stood at 2,031, although this did represent a modest slump from the 43% growth recorded the previous year. It is believed that the quickened pace of cellular immunotherapy developments in clinical and preclinical stages in 2020 when compared with 2019, will help broaden the scope of cellular immunotherapy, hence promoting the expansion and large-scale revenue generation in the cellular immunotherapy market.

How is the global cellular immunotherapy market divided into key segments?

The cellular immunotherapy market covered in this report is segmented –

1) By Therapy: Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy

2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications

3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications

Subsegments:

1) By Tumour-Infiltrating Lymphocyte (TIL) Therapy: Autologous TIL Therapy, Allogeneic TIL Therapy, Other TIL Therapy

2) By Engineered T Cell Receptor (TCR) Therapy: Alpha-Beta TCR Therapy, Gamma-Delta TCR Therapy, Other Engineered TCR Therapy

3) By Chimeric Antigen Receptor (CAR) T Cell Therapy: Autologous CAR T Cell Therapy, Allogeneic CAR T Cell Therapy, CAR T Cell Therapy For Solid Tumors, CAR T Cell Therapy For Hematologic Malignancies, Other CAR T Cell Therapy

4) By Natural Killer (NK) Cell Therapy: Autologous NK Cell Therapy, Allogeneic NK Cell Therapy, NK Cell Therapy With Engineered Modifications, Other NK Cell Therapy

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3435&type=smp

Who are the key firms paving the way for growth in the cellular immunotherapy market?

Major companies operating in the cellular immunotherapy market include Novartis International AG, Gilead Sciences Inc., Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp, AstraZeneca plc, Bristol Myers Squibb Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Adicet Bio Inc., ResTORbio Inc., Celyad SA, Merck KGaA, GlaxoSmithKline plc., Johnson & Johnson, Adaptimmune Therapeutics plc, AVROBIO Inc., Cellular Biomedicine Group Inc., Kite Pharma Inc., Juno Therapeutics Inc., Celgene Corporation, Bluebird Bio Inc., Tmunity Therapeutics Inc., Atara Biotherapeutics Inc., Fate Therapeutics Inc., Precision Biosciences Inc., Allogene Therapeutics Inc., CRISPR Therapeutics AG, Sangamo Therapeutics Inc., Intellia Therapeutics Inc., Editas Medicine Inc., Caribou Biosciences Inc., Mammoth Biosciences Inc., Synthego Corporation

Which trends are expected to transform the cellular immunotherapy market?

Firms within the cellular immunotherapy sphere are concentrating on the creation of new and superior cancer treatments through off-the-shelf allogeneic therapies. These therapies, unlike autologous therapies, are derived from donor cells rather than the patient’s own cells. They offer benefits such as cost efficiency, large scale production, speed, and quality control owing to their non-customized nature. For example, Novartis AG, a Swiss pharmaceutical company proficient in drug discovery, development, production, and commercialization, revealed in May 2022 that the US Food and Drug Administration (FDA) has granted accelerated approval for Kymriah (tisagenlecleucel) for treating adults with relapsed or refractory (r/r) follicular lymphoma (FL) who have undergone two or more systemic therapies. Furthermore, Acepodia, an American company that specializes in state-of-the-art cell immuno-technology, is set to commence a phase 1 clinical trial in August 2020 to assess ACE1702, an allogeneic, off-the-shelf NK cell therapy created for solid tumor treatment.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3435

What regions are contributing significantly to the growth of the cellular immunotherapy market?

North America was the largest region in the cellular immunotherapy market in 2023. The regions covered in the cellular immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Leukemia Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report

Colorectal Cancer Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/colorectal-cancer-drugs-global-market-report

Viral Vectors And Plasmid DNA Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What Long-Term Growth Rate is Expected for the Cellular Immunotherapy Market Between 2025 and 2034?

The scale of the cellular immunotherapy market has been expanding swiftly in the past years. It is projected to escalate from $5.72 billion in 2024 to $6.61 billion in 2025, representing a compound annual growth rate (CAGR) of 15.7%. The growth witnessed in the earlier phase is attributed to progress in cancer treatment techniques, clinical triumphs, regulatory green lights and the increasing cases of targeted diseases.

Expectations are high for a swift expansion in the cellular immunotherapy market in the coming years. Predictions suggest an increase to $11.27 billion by 2029, translating to a compound annual growth rate (CAGR) of 14.2%. The anticipated growth during the forecast period can be associated with developments in solid tumors, enhanced manufacturing processes, improvements in healthcare infrastructure, and an increase in research funding. The forecast period is likely to witness substantial trends such as investment in research and development, data from clinical trials, and the emergence of combination therapies.

Which Drivers Are Expected to Have the Greatest Impact on the Cellular Immunotherapy Market’s Growth?

The cellular immunotherapy market is anticipated to grow due to the rising scope of research and promising results from clinical trials in this area. Many companies are turning their attention to create new forms of cellular immunotherapies to combat various diseases. For instance, as per a report by the Cancer Research Institute in June 2022, a US-based organization committed to crafting immunotherapy for the prevention, treatment, and eventual elimination of all forms of cancer, there were 2,756 active cell therapy drugs in the global immuno-oncology pipeline as of April 2022. This marked a 36% rise from the overall tally of 2021 which stood at 2,031, although this did represent a modest slump from the 43% growth recorded the previous year. It is believed that the quickened pace of cellular immunotherapy developments in clinical and preclinical stages in 2020 when compared with 2019, will help broaden the scope of cellular immunotherapy, hence promoting the expansion and large-scale revenue generation in the cellular immunotherapy market.

Get Your Free Sample of the Global Cellular Immunotherapy Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=3435&type=smp

What Are the Key Firms That Are Driving Transformation in the Cellular Immunotherapy Market?

Major companies operating in the cellular immunotherapy market include Novartis International AG, Gilead Sciences Inc., Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp, AstraZeneca plc, Bristol Myers Squibb Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Adicet Bio Inc., ResTORbio Inc., Celyad SA, Merck KGaA, GlaxoSmithKline plc., Johnson & Johnson, Adaptimmune Therapeutics plc, AVROBIO Inc., Cellular Biomedicine Group Inc., Kite Pharma Inc., Juno Therapeutics Inc., Celgene Corporation, Bluebird Bio Inc., Tmunity Therapeutics Inc., Atara Biotherapeutics Inc., Fate Therapeutics Inc., Precision Biosciences Inc., Allogene Therapeutics Inc., CRISPR Therapeutics AG, Sangamo Therapeutics Inc., Intellia Therapeutics Inc., Editas Medicine Inc., Caribou Biosciences Inc., Mammoth Biosciences Inc., Synthego Corporation

What Current Trends in the Cellular Immunotherapy Market Should Industry Players Pay Attention To?

Firms within the cellular immunotherapy sphere are concentrating on the creation of new and superior cancer treatments through off-the-shelf allogeneic therapies. These therapies, unlike autologous therapies, are derived from donor cells rather than the patient’s own cells. They offer benefits such as cost efficiency, large scale production, speed, and quality control owing to their non-customized nature. For example, Novartis AG, a Swiss pharmaceutical company proficient in drug discovery, development, production, and commercialization, revealed in May 2022 that the US Food and Drug Administration (FDA) has granted accelerated approval for Kymriah (tisagenlecleucel) for treating adults with relapsed or refractory (r/r) follicular lymphoma (FL) who have undergone two or more systemic therapies. Furthermore, Acepodia, an American company that specializes in state-of-the-art cell immuno-technology, is set to commence a phase 1 clinical trial in August 2020 to assess ACE1702, an allogeneic, off-the-shelf NK cell therapy created for solid tumor treatment.

Get Instant Access to the Global Cellular Immunotherapy Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

Which Growth-Oriented Segments of the Cellular Immunotherapy Market Are Leading the Industry’s Development?

The cellular immunotherapy market covered in this report is segmented –

1) By Therapy: Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy

2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications

3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications

Subsegments:

1) By Tumour-Infiltrating Lymphocyte (TIL) Therapy: Autologous TIL Therapy, Allogeneic TIL Therapy, Other TIL Therapy

2) By Engineered T Cell Receptor (TCR) Therapy: Alpha-Beta TCR Therapy, Gamma-Delta TCR Therapy, Other Engineered TCR Therapy

3) By Chimeric Antigen Receptor (CAR) T Cell Therapy: Autologous CAR T Cell Therapy, Allogeneic CAR T Cell Therapy, CAR T Cell Therapy For Solid Tumors, CAR T Cell Therapy For Hematologic Malignancies, Other CAR T Cell Therapy

4) By Natural Killer (NK) Cell Therapy: Autologous NK Cell Therapy, Allogeneic NK Cell Therapy, NK Cell Therapy With Engineered Modifications, Other NK Cell Therapy

What Regions Are Driving Expansion in the Cellular Immunotherapy Market?

North America was the largest region in the cellular immunotherapy market in 2023. The regions covered in the cellular immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Key Parameters Define the Cellular Immunotherapy Market’s Scope?

Cellular immunotherapy refers to a sort of immunotherapy in which a patient receives T cells, an immune cell, to aid the body in fighting diseases like cancer. It is a cutting-edge kind of treatment that uses the body’s immune system to combat cancer.

Browse Through More Similar Reports By The Business Research Company:

Leukemia Therapeutics Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report

Colorectal Cancer Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/colorectal-cancer-drugs-global-market-report

Viral Vectors And Plasmid DNA Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: